Skip Navigation


European Heart Journal Advance Access originally published online on June 9, 2009
European Heart Journal 2009 30(16):1986-1994; doi:10.1093/eurheartj/ehp220
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
30/16/1986    most recent
ehp220v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cao, F.
Right arrow Articles by Wang, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cao, F.
Right arrow Articles by Wang, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up{ddagger}

Feng Cao1,{dagger},*, Dongdong Sun1,{dagger}, Chengxiang Li1,{dagger}, Kazim Narsinh2, Li Zhao1, Xue Li1, Xuyang Feng1, Jun Zhang3, Yunyan Duan3, Jing Wang4, Dingjing Liu4 and Haichang Wang1,*

1 Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
2 Department of Medicine, University of California, San Diego, CA, USA
3 Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
4 Department of Nuclear medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China

Received 2 November 2008; revised 15 April 2009; accepted 4 May 2009; online publish-ahead-of-print 9 June 2009.

* Corresponding author. Tel: +86 29 84773464, Fax: +86 29 84771024, Email: wind8828{at}gmail.com (F.C.), Tel: +86 29 84775183, Fax: +86 29 84773469, Email: wanghc{at}fmmu.edu.cn (H.W.)

Aims: To evaluate the safety profile and efficacy of bone marrow mononuclear cells (BMMNC) transplantation for ST-segment elevation myocardial infarction (STEMI) by assessing patients and their left ventricular function at up to 4 years follow-up.

Methods and results: Eighty-six patients with STEMI who had successfully undergone percutaneous coronary intervention (PCI) were randomized to receive intracoronary injection of BMMNC (n = 41) or saline (n = 45). Left ventricular ejection fraction, as evaluated by UCG, was markedly improved at 6 months (0.484 ± 0.5 vs. 0.457 ± 0.6, P = 0.001), 1 year (0.482 ± 0.7 vs. 0.446 ± 0.6, P < 0.001), and 4 years (0.505 ± 0.8 vs. 0.464 ± 0.8, P < 0.001) after BMMNC transplant when compared with control group. However, the current cell therapy did not improve the myocardial viability of the infarcted area as assessed by single-photon emission computed tomography analysis at 4 years post-transplant (0.263 ± 0.007 in BMMNC group vs. 0.281 ± 0.008 in control group, P = 0.10). During the follow-up period, one control group case (2.2%) of in-stent restenosis was confirmed by coronary angiography and underwent repeat PCI. Also during follow-up, one death (2.2%) occurred in the control group, and one patient (2.4%) in the BMMNC group had transient acute heart failure.

Conclusion: This study indicates that intracoronary delivery of autologous BMMNC is safe and feasible for STEMI patients who have undergone PCI, and can lead to long-term improvement in myocardial function.

Key Words: Bone marrow mononuclear cells • Cell therapy • ST-segment elevation myocardial infarction • Percutaneous coronary intervention • Left ventricular function

{dagger} The first three authors contributed equally to the study.

{ddagger} This work was performed in Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, 710032, China


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
T. Thum and S. Anker
The BALANCE Study: Too Early to Speculate on Mortality Effects
J. Am. Coll. Cardiol., January 19, 2010; 55(3): 263 - 264.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.